Drug Name: Elfabrio
Indications: To treat confirmed Fabry disease.
Active Ingredient: Pegunigalsidase alfa-iwxj
Company: Chiesi USA, Inc.
Approval Date: 5/9/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf